Avanir Pharmaceuticals (AVNR) Misses Q2 Loss Views by 1c/Share

Avanir Pharmaceuticals (NASDAQ: AVNR) reported Q2 EPS of ($0.13), $0.01 worse than the analyst estimate of ($0.12). Revenue for the quarter came in at $10 million versus the consensus estimate of $7.81 million.

For earnings history and earnings-related data on Avanir Pharmaceuticals (AVNR) click here.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Grandstand Limited (GRSD) Tops Q2 EPS by 5c; Offers Guidance
• Caribou Biosciences, Inc. (CRBU) Tops Q2 EPS by 7c
• Veritone (VERI) Misses Q2 EPS by 13c ; Offers Guidance